Payment overview · 2025
General Payments
$38.69
2 reported records · 2 companies
Healthcare provider profile · identity verified
Eric James Watson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ST GEORGE, SC · NPI 1952474769
Verified facts
What the public records show
CMS Open Payments records show Eric James Watson, MD received $38.69 in general payments during 2025 across 2 reported records.
ACADIA Pharmaceuticals Inc accounted for 62.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.28 | 62.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.41 | 37.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $38.69 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 584 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 553 | 127 |
| Gabapentin | Gabapentin | 431 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 90 |
| Alprazolam | Alprazolam | 396 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 363 | 80 |
| Omeprazole | Omeprazole | 319 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 289 | 40 |
| Meloxicam | Meloxicam | 267 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 50 |
| Furosemide | Furosemide | 245 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 60 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 227 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 46 |
| Metformin Hcl | Metformin Hcl | 202 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 178 | 16 |
| Losartan Potassium | Losartan Potassium | 176 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 168 | 32 |
| Eliquis | Apixaban | 165 | 25 |
| Metformin Hcl Er | Metformin Hcl | 163 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 35 |
| Pregabalin | Pregabalin | 149 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 28 |
| Ozempic | Semaglutide | 141 | 21 |
| Lorazepam | Lorazepam | 140 | 23 |
| Temazepam | Temazepam | 140 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 134 | 31 |
| Tramadol Hcl | Tramadol Hcl | 132 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 128 | 33 |
| Trazodone Hcl | Trazodone Hcl | 127 | 30 |
| Azithromycin | Azithromycin | 126 | 89 |
| Irbesartan | Irbesartan | 122 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 29 |
| Simvastatin | Simvastatin | 115 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 14 |
| Prednisone | Prednisone | 99 | 54 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 18 |
| Naproxen | Naproxen | 98 | 28 |
| Clonazepam | Clonazepam | 97 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 25 |
| Allopurinol | Allopurinol | 95 | 23 |
| Mounjaro | Tirzepatide | 95 | 11 |
| Potassium Chloride | Potassium Chloride | 95 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 16 |
| Propranolol Hcl | Propranolol Hcl | 94 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 18 |
| Diazepam | Diazepam | 80 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 80 | 17 |
| Promethazine Hcl | Promethazine Hcl | 75 | 18 |
| Sertraline Hcl | Sertraline Hcl | 75 | 16 |
| Xarelto | Rivaroxaban | 73 | 11 |
| Carvedilol | Carvedilol | 71 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 20 |
| Famotidine | Famotidine | 66 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | suppressed |
| Levofloxacin | Levofloxacin | 63 | 45 |
| Mirtazapine | Mirtazapine | 63 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 11 |
| Linzess | Linaclotide | 60 | 11 |
| Lisinopril | Lisinopril | 60 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 59 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | suppressed |
| Celecoxib | Celecoxib | 54 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Atenolol | Atenolol | 52 | 11 |
| Spironolactone | Spironolactone | 52 | 13 |
| Montelukast Sodium | Montelukast Sodium | 51 | 12 |
| Meclizine Hcl | Meclizine Hcl | 50 | 15 |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 41 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 46 | suppressed |
| Trimethoprim | Trimethoprim | 46 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Risperidone | Risperidone | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 33 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | 14 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 39 | 11 |
| Fluconazole | Fluconazole | 38 | 25 |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 27 |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38.69 · 2 records | ACADIA Pharmaceuticals Inc | NUPLAZID, VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error